Cargando…

Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease

BACKGROUND: The cellular inflammatory pattern of nonsteroidal anti‐inflammatory drug–exacerbated respiratory disease (N‐ERD) is heterogeneous. However, data on the heterogeneity of non‐eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N‐ERD patients based on clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastalerz, Lucyna, Celejewska‐Wójcik, Natalia, Ćmiel, Adam, Wójcik, Krzysztof, Szaleniec, Joanna, Hydzik‐Sobocińska, Karolina, Tomik, Jerzy, Sanak, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009799/
https://www.ncbi.nlm.nih.gov/pubmed/36973957
http://dx.doi.org/10.1002/clt2.12235
_version_ 1784906058882351104
author Mastalerz, Lucyna
Celejewska‐Wójcik, Natalia
Ćmiel, Adam
Wójcik, Krzysztof
Szaleniec, Joanna
Hydzik‐Sobocińska, Karolina
Tomik, Jerzy
Sanak, Marek
author_facet Mastalerz, Lucyna
Celejewska‐Wójcik, Natalia
Ćmiel, Adam
Wójcik, Krzysztof
Szaleniec, Joanna
Hydzik‐Sobocińska, Karolina
Tomik, Jerzy
Sanak, Marek
author_sort Mastalerz, Lucyna
collection PubMed
description BACKGROUND: The cellular inflammatory pattern of nonsteroidal anti‐inflammatory drug–exacerbated respiratory disease (N‐ERD) is heterogeneous. However, data on the heterogeneity of non‐eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N‐ERD patients based on clinical data and eicosanoid biomarkers we aimed to identify NEA endotypes potentially guiding clinical management. METHODS: Induced sputum was collected from patients with N‐ERD. Sixty six patients (49.6% of 133 N‐ERD) with NEA were included in the hierarchical cluster analysis based on clinical and laboratory data. The quality of clustering was evaluated using internal cluster validation with different indices and a practical decision tree was proposed to simplify stratification of patients. RESULTS: The most frequent NEA pattern was paucigranulocytic (PGA; 75.8%), remaining was neutrophilic asthma (NA; 24.2%). Four clusters were identified. Cluster #3 included the highest number of NEA patients (37.9%) with severe asthma and PGA pattern (96.0%). Cluster #1 (24.2%) included severe only asthma, with a higher prevalence of NA (50%). Cluster #2 (25.8%) comprised well‐controlled mild or severe asthma (PGA; 76.5%). Cluster #4 contained only 12.1% patients with well‐controlled moderate asthma (PGA; 62.5%). Sputum prostaglandin D(2) levels distinguished cluster #1 from the remaining clusters with an area under the curve of 0.94. CONCLUSIONS: Among identified four NEA subtypes, clusters #3 and #1 represented N‐ERD patients with severe asthma but a different inflammatory signatures. All the clusters were discriminated by sputum PGD(2) levels, asthma severity, and age of patients. The heterogeneity of non‐eosinophilic N‐ERD suggests a need for novel targeted interventions.
format Online
Article
Text
id pubmed-10009799
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100097992023-03-14 Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease Mastalerz, Lucyna Celejewska‐Wójcik, Natalia Ćmiel, Adam Wójcik, Krzysztof Szaleniec, Joanna Hydzik‐Sobocińska, Karolina Tomik, Jerzy Sanak, Marek Clin Transl Allergy Original Article BACKGROUND: The cellular inflammatory pattern of nonsteroidal anti‐inflammatory drug–exacerbated respiratory disease (N‐ERD) is heterogeneous. However, data on the heterogeneity of non‐eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N‐ERD patients based on clinical data and eicosanoid biomarkers we aimed to identify NEA endotypes potentially guiding clinical management. METHODS: Induced sputum was collected from patients with N‐ERD. Sixty six patients (49.6% of 133 N‐ERD) with NEA were included in the hierarchical cluster analysis based on clinical and laboratory data. The quality of clustering was evaluated using internal cluster validation with different indices and a practical decision tree was proposed to simplify stratification of patients. RESULTS: The most frequent NEA pattern was paucigranulocytic (PGA; 75.8%), remaining was neutrophilic asthma (NA; 24.2%). Four clusters were identified. Cluster #3 included the highest number of NEA patients (37.9%) with severe asthma and PGA pattern (96.0%). Cluster #1 (24.2%) included severe only asthma, with a higher prevalence of NA (50%). Cluster #2 (25.8%) comprised well‐controlled mild or severe asthma (PGA; 76.5%). Cluster #4 contained only 12.1% patients with well‐controlled moderate asthma (PGA; 62.5%). Sputum prostaglandin D(2) levels distinguished cluster #1 from the remaining clusters with an area under the curve of 0.94. CONCLUSIONS: Among identified four NEA subtypes, clusters #3 and #1 represented N‐ERD patients with severe asthma but a different inflammatory signatures. All the clusters were discriminated by sputum PGD(2) levels, asthma severity, and age of patients. The heterogeneity of non‐eosinophilic N‐ERD suggests a need for novel targeted interventions. John Wiley and Sons Inc. 2023-03-13 /pmc/articles/PMC10009799/ /pubmed/36973957 http://dx.doi.org/10.1002/clt2.12235 Text en © 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Mastalerz, Lucyna
Celejewska‐Wójcik, Natalia
Ćmiel, Adam
Wójcik, Krzysztof
Szaleniec, Joanna
Hydzik‐Sobocińska, Karolina
Tomik, Jerzy
Sanak, Marek
Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease
title Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease
title_full Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease
title_fullStr Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease
title_full_unstemmed Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease
title_short Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease
title_sort non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009799/
https://www.ncbi.nlm.nih.gov/pubmed/36973957
http://dx.doi.org/10.1002/clt2.12235
work_keys_str_mv AT mastalerzlucyna noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease
AT celejewskawojciknatalia noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease
AT cmieladam noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease
AT wojcikkrzysztof noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease
AT szaleniecjoanna noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease
AT hydziksobocinskakarolina noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease
AT tomikjerzy noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease
AT sanakmarek noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease